Vivus Inc., of Mountain View, Calif., disclosed total revenue for the first quarter of $36.7 million for the first quarter of 2014, compared to $4.1 million for the first quarter of 2013. Of the total, net product revenue was $9.1 million from sales of obesity drug Qsymia (phentermine/topiramate), compared to $4.1 million for the first quarter of 2013.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter